Published in PLoS One on July 29, 2014
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Doxorubicin-induced cardiomyopathy. N Engl J Med (1998) 9.08
Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem (1980) 5.45
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release (2008) 3.27
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Tenascin-C induced signaling in cancer. Cancer Lett (2006) 2.21
Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst (2007) 2.00
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res (2008) 1.65
Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res (2003) 1.53
Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem (2006) 1.50
Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta (2006) 1.48
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res (1989) 1.47
New frontiers in nanotechnology for cancer treatment. Urol Oncol (2008) 1.42
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res (2009) 1.35
Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv (2005) 1.32
Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res (2009) 1.28
Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci (2007) 1.27
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release (2005) 1.24
Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res (2007) 1.22
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol (1999) 1.22
Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol (2011) 1.22
Emerging nanopharmaceuticals. Nanomedicine (2008) 1.21
Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta (2003) 1.21
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm (2009) 1.18
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist (2007) 1.15
The tenascin-C knockout revisited. J Cell Sci (1999) 1.13
Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res (2002) 1.12
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem (2006) 1.05
Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm (2009) 1.04
Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res (1986) 1.03
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther (2007) 0.97
Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther (2007) 0.97
Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C. Oncogene (2001) 0.97
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer (1996) 0.97
Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res (2000) 0.95
Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharm (2002) 0.94
Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int J Nanomedicine (2012) 0.92
Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res (2008) 0.92
Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Int J Nanomedicine (2012) 0.92
Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release (2010) 0.91
Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol (2005) 0.90
Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res (2005) 0.90
Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res (1994) 0.90
Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin Cancer Res (1999) 0.90
In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull (2005) 0.89
Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia (2008) 0.88
MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res (2010) 0.87
High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B Biomed Sci Appl (1999) 0.87
Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer Chemother Pharmacol (2005) 0.87
Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J (2004) 0.86
Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release (2006) 0.85
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Mol Cancer Ther (2009) 0.83
Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo. AAPS PharmSciTech (2010) 0.82
Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations. Biomed Chromatogr (2008) 0.82
Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. PLoS One (2012) 0.82
Interaction of doxorubicin with lipid systems. Bioconjug Chem (1992) 0.81
Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther (1997) 0.81
Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell Int (2013) 0.80
Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. Interact Cardiovasc Thorac Surg (2009) 0.80
Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. J Pharm Pharmacol (2008) 0.79
Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin. J Control Release (2003) 0.79
Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes. Curr Drug Discov Technol (2011) 0.79
The effect of doxorubicin on rats that received toxic and carcinogenic benzo(a)pyrene. Folia Histochem Cytobiol (2008) 0.78
Hydration and stability of sulfatide-containing phosphatidylethanolamine small unilamellar vesicles. Biochim Biophys Acta (1999) 0.78
Sulfatide binding properties of murine and human antiganglioside antibodies. Glycobiology (2007) 0.77
Targeted delivery of doxorubicin via estrone-appended liposomes. J Drug Target (2008) 0.76
Serum aminotransferase activity as a predictor for estimation of total clearance of hepatically metabolized drugs in rats with acute hepatic failure. Biol Pharm Bull (2006) 0.75
Reduced severity of posttraumatic stress disorder associated with Val allele of Val66Met polymorphism at brain-derived neurotrophic factor gene among Chinese adolescents after Wenchuan earthquake. Psychophysiology (2016) 0.77
Sch9 regulates intracellular protein ubiquitination by controlling stress responses. Redox Biol (2015) 0.76